Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.
about
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisAndrogen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesBiomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networksState of Art of Cancer Pharmacogenomics in Latin American Populations.Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancerGenetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsGenotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.Personalized radiotherapy: concepts, biomarkers and trial designFunctional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based ChemotherapyPharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.Pharmacogenomics in oncology careThe impact of germline mutations on targeted therapy.Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.LightSNiP assay is a good strategy for pharmacogenetics test.Evaluation of person-level heterogeneity of treatment effects in published multiperson N-of-1 studies: systematic review and reanalysis.
P2860
Q26800005-D85044D0-5CA5-4D63-8A18-3488405D87FDQ26866135-D3EC2310-DB12-4A4F-8E63-CBE8B3E54707Q26991945-86B808B8-7701-40C1-9D41-2C13FC47C8F7Q33838298-D4B9661A-5466-4E5E-BF7A-C00D78FA3CA3Q34295621-704D764E-E2D2-4ACD-8B42-CEA367F02FFEQ34452900-F41C63B2-F01F-4170-AFA4-76FBFA62AFAAQ36218210-F7A53257-5F98-4DE1-8E02-B4A3BFEBFD74Q36235704-44E651AD-0852-44FE-A3F2-93B0646C8D2AQ36993563-B888CF4A-D1A9-49EB-AFCA-1C91F639DCEAQ37286470-24EF9BD8-53BF-4DA8-87E0-5AFC64164B33Q37702497-0EFC19F6-17EF-4813-B4D2-A6F61DBFFC0EQ38151546-13CEDC3B-115F-4461-8777-7E21F57CCC17Q38264774-84739EA8-A60A-4BE6-B174-8225C5CC46ABQ38539917-04BC6D52-0FC1-4CE7-BE50-C5953440BB3AQ38823143-9642607D-CAA0-4C2A-B569-1E5972E07989Q38826494-D1A2E5F4-C373-4592-A019-B7918782407FQ41430035-D6F78A64-0ECA-4879-A1B5-B15D4A817975Q41512367-F616DC1D-390E-4206-A676-97AA3C2F8BF3Q55246416-0D39E4C1-0B11-42FD-960A-5F1D8E4636D5
P2860
Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Use of pharmacogenetics for pr ...... posure, response and toxicity.
@en
type
label
Use of pharmacogenetics for pr ...... posure, response and toxicity.
@en
prefLabel
Use of pharmacogenetics for pr ...... posure, response and toxicity.
@en
P2860
P356
P1476
Use of pharmacogenetics for pr ...... posure, response and toxicity.
@en
P2093
Daniel L Hertz
Howard L McLeod
P2860
P2888
P304
P356
10.1038/JHG.2013.42
P577
2013-05-16T00:00:00Z